(Q46011754)

18 December 2017

title

Statin-associated adverse cognitive effects: survey results from 171 patients. (English)

1 reference

18 December 2017

0 references

Marcella A Evans

1

1 reference

18 December 2017

Beatrice A Golomb

series ordinal

2

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

18 December 2017

published in

Pharmacotherapy

1 reference

18 December 2017

volume

29

1 reference

18 December 2017

issue

7

1 reference

18 December 2017

page(s)

800-811

1 reference

18 December 2017

Timing of new black box warnings and withdrawals for prescription medications

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Coxibs, science, and the public trust.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Consumer adverse drug reaction reporting: a new step in pharmacovigilance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Clinical perspectives of statin-induced rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

How common is rhabdomyolysis in patients receiving lipid-lowering therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Simvastatin-induced decline in cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Short-term memory loss associated with rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Cognitive impairment associated with atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Simvastatin-associated memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statin-associated memory loss: analysis of 60 case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Effects of lovastatin on cognitive function and psychological well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Low and lowered cholesterol and total mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Transient global amnesia--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Genetic risk factors associated with lipid-lowering drug-induced myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Peripheral arterial disease: morbidity and mortality implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statin therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Estrogen and Alzheimer's disease: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Statin-associated peripheral neuropathy: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Peripheral neuropathy associated with simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Volume reduction of the entorhinal cortex in subjective memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Cognitive deficits 3 to 6 years before dementia onset in a population sample: the Honolulu-Asia aging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

Subjective memory deterioration and future dementia in people aged 65 and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.7.800

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.7.800

1 reference

18 December 2017

1 reference

18 December 2017